NCTC
DGX icon

New Covenant Trust Company’s Quest Diagnostics DGX Stock Holding History

New Covenant Trust Company’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-75
Closed -$9.98K – 171
2024
Q1 		$9.98K Buy
+75
New +$9.73K 0.01% 340

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

New Covenant Trust Company's DGX Position: Q2 2024 in Review

New Covenant Trust Company sold out of Quest Diagnostics (DGX) in Q2 2024, closing a stake of 75 shares — an estimated $9.98K sold.

New Covenant Trust Company first reported a position in DGX in Q1 2024 and held it in 1 quarter. The position peaked at $9.98K in Q1 2024. 837 funds tracked by Wall St. Rank hold DGX as of Q2 2024.

  • New Covenant Trust Company reported no remaining Quest Diagnostics position as of Q2 2024 after selling out during the quarter.
  • New Covenant Trust Company sold 75 Quest Diagnostics shares in Q2 2024, an estimated $9.98K.
  • New Covenant Trust Company first reported a position in Quest Diagnostics in Q1 2024 and held it in 1 quarter.
  • New Covenant Trust Company's Quest Diagnostics position peaked at $9.98K in Q1 2024.
  • 837 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2024.

Based on New Covenant Trust Company's 13F filing for Q2 2024, filed 30 Jul 2024.